Description: BioNexus Gene Lab Corporation, a molecular diagnostics company, develops and commercializes molecular diagnostic tests for the early detection of diseases and personalized health management, primarily focusing on cardiovascular, diabetes, and cancer-related indications primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of cancers, including nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon; bowel diseases, such as colitis and Crohn; and osteoarthritis. The company markets its blood screening process to health care providers, such as doctors, laboratories, and hospitals. BioNexus Gene Lab Corporation was founded in 2017 and is based in Kuala Lumpur, Malaysia.
Home Page: www.bionexusgenelab.com
Tower B, Avenue 3
Kuala Lumpur,
59200
Malaysia
Phone:
60 1 307 241 6898
Officers
| Name | Title |
|---|---|
| Mr. Su-Leng Tan | CEO, Acting CFO, Secretary & Director |
| Mr. Kwan Wah Chan | Marketing Manager |
| Mr. Too Kam Tham | Managing Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Materials |
|---|---|
| GIC Group: | Materials |
| GIC Industry: | Chemicals |
| GIC Sub-Industry: | Specialty Chemicals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5187 |
| Price-to-Sales TTM: | 0.5674 |
| IPO Date: | 2020-09-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 30 |